Share on StockTwits
 

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reaffirmed by investment analysts at TheStreet in a note issued to investors on Tuesday, American Banking News.com reports.

The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.”

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 168,511 shares of the stock in a transaction dated Friday, February 7th. The shares were purchased at an average price of $286.78 per share, with a total value of $48,325,584.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 305.01 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $154.16 and a 52 week high of $319.83. The stock has a 50-day moving average of $282.5 and a 200-day moving average of $279.8. The company has a market cap of $29.960 billion and a P/E ratio of 43.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, February 11th. The company reported $2.24 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter last year, the company posted $1.47 earnings per share. Regeneron Pharmaceuticals’s revenue was up 47.0% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $3.91 earnings per share for the current fiscal year.

REGN has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 15th. They now have a $331.00 price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, January 10th. They now have a $340.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $323.00 to $344.00 in a research note on Friday, December 20th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $305.66.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.